However, patients with HPV-positive HNSCC have a higher three-year survival rate, which may be because HPV-positive HNSCC is more sensitive to radiotherapy and chemotherapy via the complete p53-mediated apoptotic response [44] and more patients are willing to receive multidisciplinary treatment [26,45] Besides, the extant literature indicated that the risk factors and demographic and tumor characteristics of HPV-positive patients differed from those of HPV-negative patients [46]. Here, TP53 is linked to head and neck squamous cell carcinoma.